Milestone-led biotech revenue remains overshadowed by research spending and external financing
Heidelberg Pharma’s history shows irregular partner- and milestone-linked revenue against sustained research costs, recurring losses, and negative operating cash flow. Funding needs have been met through episodic equity issuance and partnership or royalty financing rather than internally generated cash.